[fr] L'angiogenèse tumorale est une caractéristique commune à toutes les tumeurs. Ce nouveau réseau vasculaire tumoral présente des anomalies structurelles et fonctionnelles conduisant inévitablement à une perfusion tumorale hétérogène et à l'apparition de zones hypoxiques. Classiquement, l'hypoxie tumorale réfère à une inadéquation spatiale entre les vaisseaux et les cellules tumorales (i.e. hypoxie chronique). Elle confère aux cellules tumorales une résistance aux traitements et favorise les métastases. L'aspect temporel du phénomène est complètement négligé dans l'hypoxie chronique. L'hypoxie intermittente (HI), permet de tenir compte de l'aspect transitoire et temporel du phénomène. L'HI se définit comme une fluctuation de la p02 due à des arrêts transitoires du flux sanguin dans les vaisseaux tumoraux. Le compartiment tumoral et le compartiment vasculaire souffrent tous deux de l'hypoxie. L'HI étend donc le concept d'hypoxie tumorale au réseau vasculaire et aux cellules qui composent les vaisseaux. Les conséquences sont une plus grande résistance de la tumeur aux traitements de radio- et de chimiothérapie, une augmentation des métastases, mais également une résistance vasculaire accrue avec une diminution de l'apoptose des cellules endothéliales et une potentialisation de l'angiogenèse. L'identification et la compréhension des causes et des origines de l'HI permettent l'édification de nouvelles approches thérapeutiques. [en] Angiogenesis is a hallmark of tumours. The newly formed tumour vessels are structurally and functionally abnormal leading to tumour perfusion heterogeneities and subsequently to the development of hypoxic areas. Generally, tumour hypoxia refers to an increasing distance between vasculature and tumour cells (i.e. chronic hypoxia). Chronic hypoxia promotes tumour resistance to treatments and metastasis. The temporal aspect of hypoxia is completely neglected in chronic hypoxia. Intermittent hypoxia (HI) takes the transient and temporal aspect of hypoxia into account. HI is defined as pO2 fluctuations in tumour vessels secondary to transient arrest of tumour blood flow. IH extends the concept of tumour hypoxia to tumour vessels and vascular cells. Transient arrest of tumour blood flow promotes tumour resistance to radio- and chemotherapy treatments and favours metastasis. Moreover, IH protects tumour vessels and endothelial cells against pro-apoptotic stresses and promotes angiogenesis. A comprehensive dissection of the mechanisms leading to IH allows the development and establishment of new therapeutic approaches.
Disciplines :
Oncology
Author, co-author :
MARTINIVE, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
COUCKE, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Language :
English
Title :
La vascularisation tumorale en tant que source de résistance aux traitements de radiothérapie et chimiothérapie
Alternative titles :
[en] WHEN TUMOUR PERFUSION IS AT THE ORIGIN OF THE TUMOUR RESISTANCE TO RADIOTHERAPY AND CHEMOTHERAPY TREATMENTS: A NEW VIEW OF TUMOUR VASCULARISATION
Publication date :
2010
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Carmeliet P, Jain RK. - Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
Brahimi-Horn MC, Chiche J, Pouyssegur J. - Hypoxia and cancer. J Mol Med, 2007, 85, 1301-1307.
Semenza GL. - HIF-1 and tumor progression: patho-physiology and therapeutics. Trends Mol Med, 2002, 8, S62-67.
Semenza GL. - Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol, 2000, 35, 71-103.
Chaudary N Hill RP. - Hypoxia and metastasis in breast cancer. Breast Dis, 2006, 26, 55-64.
Chaudary N Hill RP. - Hypoxia and metastasis. Clin Cancer Res, 2007, 13, 1947-1949.
Cairns RA, Khokha R, Hill RP. - Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med, 2003, 3, 659-671.
Erickson K, Braun RD, Yu D, et al. - Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation. Cancer Res, 2003, 63, 4705-4712.
Dewhirst MW. - Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res, 2007, 67, 854-855.
Reinhold HS, Blachiwiecz B, Blok A. - Oxygenation and reoxygenation in «sandwich» tumours. Bibl Anat, 1977, 15, 270-272.
Ansiaux R, Baudelet C, Jordan BF, et al. - Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined anti-tumor therapy. Cancer Res, 2006, 66, 9698-9704.
Crokart N, Jordan B F, Baudelet C, et al. - Early reoxy-genation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys, 2005, 63, 901-910.
Dewhirst MW, Cao Y, Moeller B. - Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer, 2008, 8, 425-437.
Kirkpatrick JP, Cardenas-Navia LI, Dewhirst MW. - Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. Int J Radiat Oncol Biol Phys, 2004, 59, 822-833.
Moeller BJ, Cao Y, Vujaskovic Z, et al. - The relationship between hypoxia and angiogenesis. Semin Radiat Oncol, 2004, 14, 215-221.
Pries AR, Cornelissen AJ, Sloot AA, et al. - Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol, 2009, 5, e1000394.
Sonveaux P, Dessy C, Martinive P, et al. - Endothe-lin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res, 2004, 64, 3209-3214.
Martinive P, De Wever J, Bouzin C, et al. - Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther, 2006, 5, 1620-1627.
Bouzin C, Feron O. - Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat, 2007, 10, 109-120.
Martinive P, Defresne F, Bouzin C, et al. - Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res, 2006, 66, 11736-11744.
Martinive P, Defresne F, Quaghebeur E, et al. - Impact of cyclic hypoxia on HIF-1alpha regulation in endothe-lial cells-new insights for anti-tumor treatments. FEBS J, 2009, 276, 509-518.
Cairns RA, Kalliomaki T, Hill RP. - Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res, 2001, 61, 8903-8908.
Toffoli S, Roegiers A, Feron O, et al. - Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis, 2009, 12, 47-67.
Toffoli S, Feron O, Raes M, et al. - Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothe-lial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta, 2007, 1773, 1558-1571.
Eberhard A, Kahlert S, Goede V, et al. - Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res, 2000, 60, 1388-1393.
Feron O. - Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci, 2004, 25, 536-542.
Jain RK. - Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med, 2001, 7, 987-989.
Sonveaux P. - Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol, 2008, 86, 300-313.
Sonveaux P, Dessy C, Brouet A, et al. - Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J, 2002, 16, 1979-1981.
Sonveaux P, Jordan BF, Gallez B, et al. - Nitric oxide delivery to cancer: why and how? Eur J Cancer, 2009, 45, 1352-1369.
Sonveaux P, Lobysheva, II, Feron O, et al. - Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda), 2007, 22, 97-112.
Bagnato A Rosano L. - The endothelin axis in cancer. Int J Biochem Cell Biol, 2008, 40, 1443-1451.
Bagnato A Natali PG. - Targeting endothelin axis in cancer. Cancer Treat Res, 2004, 119, 293-314.
Hoogsteen IJ, Pop LA, Marres HA, et al. - Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 2006, 64, 83-89.
Kaanders JH, Bussink J van der Kogel AJ. - Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol, 2004, 14, 233-240.
Kaanders JH, Pop LA, Marres HA, et al. - ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2002, 52, 769-778.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
